Therefore, it can be concluded that based on the expression of FLT3-lTD and NPM-1 as well as miR-34a, miR-191, miR-199b, the response to induction chemotherapy in AML patients can be predicted quite well. This evidence concerns the gene NPM1 and acute myeloid leukemia.